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The aim of this study was to survey factors related to EULAR good response, the DAS-28 definition of remission,
ACR 50 response, sustained response to tumor necrosis factor inhibitors (TNF-I) therapy in biologic naïve patients
with refractory rheumatoid arthritis. This was a single center observational clinical prospective 2 years’ study, EULAR
response criteria, DAS 28, HAQ and radiographic changes were recorded. Eighty patients included (64 females and
16 males, mean age was 48.4 + −17.9 years, mean disease duration 7.3 + −5.9 years). At 6 months 70% achieved
EULAR good response, 51.8% achieved DAS-28 remission. Good response/sustained responses inversely correlated
with baseline DAS-28 and radiographic erosions P <0.05. EULAR good response/remission by 6 months, sustained
response at 2 years positively correlated with the decline in RF titers (r = 0.33, P < 0.05 & r = 0.30, P < 0.03 respectively),
negatively correlated with the baseline HAQ. Regression analysis identified higher serum hemoglobin concentration,
lower baseline HAQ scores, and the absence of radiographic erosions as significant predictors of good as well as
sustained responses after adjustment for potential covariates. Methotrexate was associated with favorable responses
and remission at 6 months (ORs = 1.13, 1.30 respectively). The study concluded that a lower baseline DAS-28 and HAQ
scores, the lack of radiographic erosions favored EULAR good response and were significant predictors of sustained
response to TNF-I.
Keywords: EULAR good response; DAS-28 remission; Sustained responses; Refractory rheumatoid arthritis; Tumor
necrosis factor inhibitorsIntroduction
Rheumatoid Arthritis is a systemic autoimmune inflam-
matory disease of indefinite etiology. The disease specific-
ally affects the synovial joints contributing to significant
synovial inflammation, progressive joint destruction and
deformity of the affected joints. RA affects approximately
1% of adults all over the world with the diagnosis usually
established between the third and fifth decade of life.* Correspondence: rmhamdy@yahoo.com
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reproduction in any medium, provided the origWomen are 2 to 3 times more likely to be diagnosed than
men. The disease might additionally contribute to extra-
articular multi-organ inflammation with variable outcome.
Improperly treated the disease might lead to significant
morbidity and incapacitation. For decades the conven-
tional synthetic DMARDs (csDMARDs) have been the
corner stone for the management of RA with methotrex-
ate being the anchor drug in most of the designed regi-
mens. Multiple studies and real life reports have
documented that even with the highest standards of care
with the use of csDMARDs either alone or in combina-
tions up to 60% of the affected cases with RA fail to
achieve successful remission. Within the last decade the
field of therapeutics have witnessed an evolution in theis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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the lead of the Tumor necrosis factor inhibitors (TNF-I)
as the first line biologic drugs (Burmester GR et al. 2012;
Wolfe and Michaud 2010; Nozaki et al. 2013; Mohammed
et al. 2014; Nam et al. 2010; Hetland et al. 2010; Gartle-
hner et al. 2006; Wolfe and Michaud 2010; Gaujoux-Viala
et al. 2010).
The aim of the current study was to prospectively sur-
vey the factors related to achieving an EULAR good/re-
mission using the DAS-28 disease activity score and
investigate predictors of a sustained response in a popula-
tion of biologic naïve patients with refractory rheumatoid
arthritis who receive tumor necrosis factor inhibitors
TNF-I.
Methods
This is a single center observational clinical study in a
cohort of biologic naïve Refractory RA patients initiating
their first line biologic treatment of TNF-inhibitors
(infliximab, adalimumab or etanercept each administered
based on an agreement between the patient and the treat-
ing physician with special considerations). The study was
conducted at the Rheumatology section/Internal Medicine
Department, Alhada Armed Forces Hospital, Kingdom of
Saudi Arabia throughout a period of two years October
2010- October 2012. TNF-Is were given as recommended
by the manufacturers (Infliximab 3-5 mg/kg intravenous
infusion, Adalimumab 40 mg subcutaneous every 2 weeks,
etanercept 50 mg subcutaneous weekly). Authors used the
STROBE guidelines for observational studies for construc-
tion of their research checklist. The study was approved
by the organizational ethics committee and was conducted
in accordance with World Medical Association Helsinki
Declaration of ethics (Adopted by the 18th WMA General
Assembly, Helsinki, Finland, June 1964). All the patients
included gave informed consents prior to the initiation of
TNF-I biologic therapy.
Inclusion criteria:
– All patients who satisfied the ACR/EULAR 2010 for
early rheumatoid arthritis or ACR-1997 criteria
for established RA.(Arnett et al. 1988;
Aletaha et al. 2010)
– Biologic naïve RA patients who failed to achieve
remission or low disease activity despite cs
DMARDs monotherapy or combinations for
at least 6 months.
Exclusion criteria:
– RA patients who were previously or are currently
receiving biologic drugs.
– Patients with autoimmune diseases other than RA.– Infections: tuberculosis, hepatitis B, C, other active
or incompletely treated bacterial, viral or fungal
infections.
– Patients with heart failure grade III-IV NYHA,
interstitial pulmonary disease, untreated malignancies.
Data were prospectively gathered over a follow up
period of 2 years. The following clinical data were re-
corded; patients’ demographics, simplified 28 swollen
tender joint score Disease Activity Score (DAS 28), ACR
50 response, disability score using health assessment
questionnaire (HAQ score of 0–3 based on severity of
functional impairment), visual analogue scale pain score
(VAS-pain with 0 = no pain and 10 = very severe pain),
assessment for the presence of radiographic erosions and
serology profile (rheumatoid factor, anti-citrullinated C
peptide) were recorded. The primary outcome measure of
the study was to identify responders who achieved the
European League Against Rheumatism (EULAR) good re-
sponses as assessed by DAS score at 6 months (VAN
GESTEL AM et al. 1996) and survey the major differences
between responders versus non responders that favored
an early good response or remission, ACR-50 responses at
6 months were additionally taken. The secondary outcome
measure was to identify the percentage of patients sustain-
ing their response over 2 years. Patients who fail to
respond to the introduced 1st TNF-I or lose response to
one anti TNF will be classified as non- responders.
Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Package for the Social Science; SPSS Inc., Chicago, IL,
USA) version 19 for Microsoft Windows. Quantitative
data were statistically described in terms of mean and
standard deviations (±SD), qualitative data were pre-
sented as median and interquartile ranges. Within group
comparison of quantitative variables was done using
Anova F-test with posthoc multiple group comparisons.
For comparing categorical variables, Chi square (χ2) test
was performed. Exact test was used instead when the ex-
pected frequency is less than 5. P values less than 0.05
was considered statistically significant. Pearson correl-
ation was used for quantitative variables, spearman rank
correlation was used for qualitative variables. Multivari-
ate logistic regression analysis was used for identification
of factors associated with good EULAR response/
remission response at 6 months and predictors of
sustained response at 2 years in the study group.
Results
A total of 80 patients were included in the study 64
females (80%) and 16 males (20%), having a mean age
of 48.4 + −17.91 years a mean disease duration of
7.29 + −3.93 years and a mean baseline DAS-28 of 6 ± 1,
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mean CRP of 35.18 + −31.65 mg/l. Radiographic erosions
were detected in 50% (n = 40) of the study population at
baseline. The baseline demographic and clinical character-
istics are displayed in Table 1.At 6 months from initiation of therapy results showed that
Thirty patients were receiving adalimumab, 30 patients
receiving infliximab and 20 patients receiving etanercept.
Results of the study revealed that by completion of
6 months from initiation of therapy 70% of the patients
(56) achieved the EULAR good response, with 51.8% pa-
tients (n = 29) of the 56 responders having achieved
DAS-28 definition of remission (<2.6). The baseline dif-
ferences between the EULAR good responders and the
inadequate responders are displayed in Tables 2 and 3.Analysis of correlations between the different disease
related parameters and the type of response perceived
with TNF-I therapy results of this study showed that
At 6 months achieving the EULAR good response using the
DAS-28/ or achieving DAS-28 definition for remission dir-
ectly correlated with a high positive titers of IgM rheuma-
toid factor and higher Hb% at baseline (r = 0.30 & 0.30,
P < 0.05, respectively) and inversely correlated with baseline
DAS-28 and radiographic scoring (r =−0.81 & -0.75,
P < 0.01 respectively).Table 1 The baseline demographic and clinical
characteristics of the study group
Descriptive parameter Range Mean ± S.D
Age 16-85 years 48.26 ± 17.91
Disease duration 1-20 years 7.29 ± 3.93
ESR 8-119 mm/hr 51.00 ± 25.30
CRP 6-136.50 mg/l 35.18 ± 31.65
Hemoglobin 10-16gm/dl 11.56 ± 1.30
Rheumatoid factor 0-849 141.09 ± 157.88
Anti-CCP 0-450 230.05 ± 156.35
DAS 3-7.5 6.0 ± 1.0
HAQ 0.5-8 1.30 ± 0.71
VAS 5-10 6.70 ± 0.95
Medications: Number of patients Percentage%
Conventional DMARDs 58 72.5
Methotrexate 64 80
Oral corticosteroids 53 66.2
Non-steroidal drugs 80 100
Abbreviations: ESR: erythrocyte sedimentation rate, CRP: C- reactive protein,
Anti-CCP: anti-citrullinated C peptide, DAS-28: disease activity score, HAQ:
health assessment questionnaire, VAS: visual analogue scale for pain.At 2 years
Results showed that 38 patients out of the initially
responding 56 patients (corresponding to 47.5% of the
population studied, 67.8% of the responders) were still
sustaining their initial good response by the completion
of 2 years of follow up. Eighteen patients were consid-
ered as non-responders including 10 patients who devel-
oped secondary loss of response and were shifted to a
second line biologic, while 8 patients dropped out of the
study. Results showed that a sustained response at
2 years positively correlated with sero-positivity to RF
and baseline Hb% (r = 0.30 & 0.33, P <0.05 respectively)
and inversely correlated with baseline DAS-28, HAQ
and radiographic erosions (r = −0.85, −0.74, −0.77 respect-
ively, P < 0.01). The details of the correlations between the
different assessment parameters and the treatment out-
come in the studied patients are displayed in Table 4.
Multivariate regression analysis
After adjustment for confounders showed that the con-
comitant use of methotrexate was identified as a positive
predictor of good EULAR response and DAS-28 remis-
sion at 6 months (ORs = 1.13, 1.30, CI = 0.15-2.2, 0.37-
10.8, respectively), also the use of csDMARDs combina-
tions was associated by EULAR good response (ORs =
1.35, CI = 0.07-7.36). On the other hand, a higher base-
line DAS was identified as a negative predictor for a
good EULAR (ORs = 1.20, CI = 3.23-31.78). However, the
use of oral corticosteroids didn’t prove to affect the type
of response in the studied patients (P > 0.05). The study
couldn’t find any significant predictive value for varia-
tions in age, gender, or disease duration.
At the end of the study period (completion of 2 years
follow up) results of regression analysis showed that the
presence of higher baseline serum hemoglobin concen-
trations, sero-positivity to IgM rheumatoid factor were
in favor of a better response yet significance value was
weak whereas, a lower baseline HAQ score (correspond-
ing to lesser functional disability) and the absence of
radiographic erosions at inclusion as significant predic-
tors of sustained response to TNF-I in the studied group
Table 5.
Discussion
The introduction and progressive developments of
biologic disease modifying anti- rheumatic drugs have
greatly influenced the treatment paradigm as well as
treatment outcome in patients with inflammatory arth-
ritis. Till present even with the amazing advent in this
domain together with the expanding list of biologic
DMARDs, anti-tumor necrosis factor therapy or tumor
necrosis factor inhibitors remain on top of the list. The
comparative effectiveness of the three commonly used
anti-TNF infliximab, etanercept and adalimumab didn’t
Table 2 The differences between responders and non responders at inclusion in the study (0 months of follow up)
Parameter Responders (n = 56) Non-responders (n = 24) Significance
Mean ± S.D Mean ± S.D P-value
Age 47.84 ± 18.89 49.64 ± 15.70 P > 0.05
Disease duration 7.66 ± 4.11 6.59 ± 3.41 P > 0.05
Rheumatoid factor titers 169.95 ± 176.19 73.80 ± 74.58 P < 0.01**
ESR 51.40 ± 24.70 49.97 ± 26.93 P > 0.05
C-reactive protein 36.12 ± 34.27 33.10 ± 25.19 P > 0.05
Baseline-HAQ 1.25 ± 0.33 1.24 ± 0.34 P > 0.05
Baseline DAS-28 6.32 ± 0.62 5.34 ± 1.38 P < 0.01**
Baseline VAS 6.77 ± 0.97 6.51 ± 0.90 P > 0.05
Hemoglobin 11.59 ± 1.30 11.36 ± 1.06 P > 0.05
*P-value: significant < 0.05. **P-value: highly significant < 0.01. Abbreviations: ESR: erythrocyte sedimentation rate, HAQ: health assessment questionnaire,
DAS: disease activity score, VAS: visual analogue scale.
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including one meta-analysis of 26 published placebo-
controlled RCTs of patients with RA in MTX-resistant
populations where the investigators weren’t able to show
significant variations in efficacy among the 3 TNF inhib-
itors. (Hetland et al. 2010; Gartlehner et al. 2006)
Despite the multiplicity of such published trials discuss-
ing the efficacy of biologic Tumor necrosis Factor inhibi-
tors in refractory rheumatoid arthritis (RA), studies
displaying predictors of good response to such therapy
in the daily life clinical practice remain insufficient and
heterogeneous demanding continued testing of such pre-
dictors within different ethnic populations and at differ-
ent levels of rheumatology practice (Scott and Kingsley
2006; Taylor and Feldmann 2009; Grewal 2009; Canhão
et al. 2012).
To our knowledge this study is the first to scrutinize
predictors of response to TNF-I in patients with refrac-
tory RA who started their first line TNF-I and were pro-
spectively followed up for response over 2 years in this
region of KSA. This was a single center prospective ob-
servational study that included eighty RA patients who
were eligible for inclusion and consented to receive
TNF-I biologic therapy. The goal of this study wasn’t to
measure comparative effectiveness of the three used
TNF-I to each other but to investigate factors related toTable 3 The main differences in the defined assessment
measures with TNF-I at 6 months
Measures Responders Non responders Significance
P-value
ESR 23.56 ± 13.58 28 ± 16.87 <0.05*
CRP 6.66 ± 4.81 14.82 ± 17.90 <0.05*
Hb% 12.61 ± 1.09 12.01 ± 0.87 >0.05
DAS-28 2.80 ± 1.15 4.35 ± 1.24 <0.05*
RF at 6 months 118.84 ± 127.55 66.60 ± 74.16 <0.05*
*P value< 0.05 is considered statistically significant.achieving an early EULAR good response/remission (re-
mission is defined as DAS score < 2.6) as assessed by
changes in DAS-28 score at 6 months and to pick up
possible predictors of sustained response to therapy by
completion of the study period (2 years). Patients who
achieved a good response or went into remission at
6 months were classified as responders, whereas patients
who failed to achieve a satisfying response, developed
drug related serious adverse events or were shifted to
another biologic were considered as non-responders.
The study successfully completed the observation and
recording of the desired outcome measures with results
at 6 months showing that the majority of the RA popu-
lation included (70%, n = 56) achieved a good EULAR
response on TNF-I, with more than half of the re-
sponders 51.8% (n = 29) satisfying the DAS-28 definition
of remission at 6 months. The study showed that RA pa-
tients who achieved an early response at 6 months were
found to have significantly higher IgM rheumatoid factor
titers at baseline compared to non-responders (mean
169.95 ± 176.19 mg/l, P <0.01). Such statistical conclu-
sions were further supported by results of the correla-
tions between the patterns of responses perceived during
the assessment period and the baseline (at inclusion)
disease related/patient related features. The study found
that an early good response and/or remission at 6 month
significantly correlated with higher Ig M rheumatoid
factor titers and higher hemoglobin concentrations at
inclusion, yet inversely correlated with the baseline
DAS-28, the HAQ score and the presence of radio-
graphic erosions. At 2 years the study showed that 67.8%
of the responders were still sustaining their response to
TNF-I. The pertinence of sustained response at 2 years
positively correlated with sero-positivity to RF and Hb% at
inclusion and inversely correlated with baseline DAS-28,
HAQ and radiographic scoring. The continued use of
methotrexate as an anchor drug was associated with a good
EULAR response and DAS-28 remission at 6 months, also
Table 4 The correlations between the different assessment






At 6 months At 6 months At 2 years
Disease duration r = − 0.16 r = −0.05 r = − 0.10
P > 0.05 P > 0.05 P > 0.05
Positive IgM RF
at baseline
r = 0.30 r = 0.31 r = 0.30
P = < 0.05* P < 0.05* P < 0.05*
Positive Anti-CCP
at baseline
r = 0.18 r = 0.08 r = 0.14
P > 0.05 P = 0.35 P > 0.05
Baseline
Hemoglobin
r = 0.39 r = 0.30 r = 0.33
P < 0.05* P < 0.05* P < 0.05*
Baseline DAS 28 r = − 0.81 r = − 0.74 r = − 0.85
P < 0.01** P <0.01** P < 0.01*
Baseline HAQ r = − 0.08 r = − 0.18 r = − 0.74
P > 0.05 P < 0.05* P < 0.01**
Baseline VAS r = 0.12 r = − 0.06 r = − 0.17




r = − 0.75 r = − 0.80 r = − 0.77
P < 0.01** P = 0.01** P <0.01**
Declining RF
titers
r = 0.33 r = 0.30 r = 0.30
P <0.05* P < 0.05* P < 0.05*
*P-value: significant < 0.05. **P-value: highly significant < 0.01. Abbreviations:
ESR: erythrocyte sedimentation rate, HAQ: health assessment questionnaire,
DAS: disease activity score, VAS: visual analogue scale.
Table 5 Factors related to sustained responsiveness in
the study population
Parameter Significance
Disease duration t = −1.92
P = 0.05
ESR t = −0.98
P = 0.32
CRP t = 0.09
P = 0.92
Hemoglobin t = 3.71
P = 0.0001**
Rheumatoid factor t = 2.17
P = 0.03
Anti-CCP t = 0.10
P = 0.91
DAS-28 t = −0.27
P = 0.78
HAQ t = −2.71
P = 0.008**
VAS t = −2.01
P = 0.04*
Combination t = −1.01
P = 0.92
Erosive lesions t = −2.20
P = 0.03*
*P-value: significant < 0.05. **P-value: highly significant < 0.01.
Abbreviations: ESR: erythrocyte sedimentation rate, HAQ: health assessment
questionnaire, DAS: disease activity score, VAS: visual analogue scale.
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in combination with the used TNF-I was associated by
EULAR good response and ACR 50 responses. However,
the use of oral corticosteroids (prednisolone) wasn’t shown
to affect the type of response in the studied patients. Higher
baseline DAS was identified as a negative predictor for a
good EULAR and DAS remission, sustained response and/
or ACR 50 responses. Disease duration didn’t appear to
affect the response to biologic therapy in the studied popu-
lation. The study couldn’t find any significant predictive
value for variations in age, gender, or disease duration
among the studied RA patients.
Results of the current study didn’t seem far from that re-
ported in late studies including some trials by the British
study (BSRBR) by Hyrich et al. 2006, GISEA study by Man-
carella et al. 2007, the ReAct study by Bombardieri et al.
2007, Kristensen et al. 2008 and the German study by Klei-
nert et al. 2012, amongst others in several points particularly
regarding continued use of baseline methotrexate or con-
ventional DMARDS in combination with biologics. (Kris-
tensen et al. 2008; Hyrich et al. 2006; Kleinert et al. 2012;
Mancarella et al. 2007; Bombardieri et al. 2007; Breedveld
et al. 2006; Maini et al. 1999; Van der Heijde et al. 2007; StClair et al. 2004; Nozaki et al. 2010; Potter et al. 2009) The
authors could identify the use of methotrexate and conven-
tional DMARDs as significant contributors to good clinical
outcomes a conclusion shared by the current study. Add-
itionally important results of the current study illustrated
that a low HAQ corresponding to a better functional status
and low DAS score at inclusion favored a good early re-
sponse to biologic TNF-I. Unlike that reported by Hetland
et al. 2010, were the authors found that older age and con-
comitant use of corticosteroids were negative predictors of
good response, (Hetland et al. 2010) the study wasn’t able
to detect any significant influence of age, gender or oral
corticosteroid use on the pattern or timing of responses
recorded.
The existence of RF especially IgM-RF (Abs to conserved
region of IgG class Igs) with the combined detection of
additional isotypes IgA-RF remain one of the diagnostic
criteria in RA and in multiple reports its’ existence in high
titers corresponded to severe erosive disease mandating ag-
gressive therapy. There has been a lot of conflicting results
regarding the influence of TNF-I and conventional
DMARDs on serum RF levels in RA as well as the possible
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to TNF-I. The exact mechanisms by which TNF-I affect
rheumatoid factor remains unclear as it is not known
whether TNF-I are capable of direct blockage of RF pro-
duction or not. However, infliximab therapy has been
proven to reduce the number of synovial infiltration cells,
including plasma cells. RF-producing cells are present in
the inflamed rheumatoid synovium and because the local
environment may favour synovial RF production, rheuma-
tologists might expect that the reduction in inflammatory
lymphoplasmacytic infiltration into the rheumatoid syno-
vium would contribute to a reduced production of RF. A
number of published studies coincided in the finding that
a positive IgM RF was related to a poor response to TNF-I,
other studies found a correlation between the declining
levels of autoantibodies with TNF-I and the response,
whilst in a late study by Klaasen et al. 2009 and another
meta-analysis by Salgado et al. 2014 the investigators re-
ported that a positive RF status doesn’t correlate with the
EULAR good response or remission. In the current study
the investigators identified that patients with higher
baseline IgM rheumatoid factor and higher baseline
hemoglobin achieved a better response on anti-TNF
therapy, however the correlations were of moderate to
weak significance furthermore, the achievement of good
response and remission correlated with the decline in
rheumatoid factor titers which was also a weak correlation.
Such finding has been reported in some other studies
(Nozaki et al. 2010; Potter et al. 2009; Klaasen et al. 2009;
Salgado et al. 2014; Atzeni et al. 2006; Yazdani-Biuki et al.
2005; Smeets et al. 2003; Klaasen et al. 2011; Bruns et al.
2009; Bobbio-Pallavicini et al. 2007).
Because results of clinical trials do not always mirror
an exact of what rheumatologists face in real life daily
practice, observational studies and short reports still rep-
resent an important contributor to the knowledge bank
in the field of research concerning the use of biologic
DMARDs in refractory RA. Despite that researchers
might face the challenge that such studies are usually
open labelled non-randomized which might generate
methodological limitation such drawback can be mini-
mized by avoidance of separate analysis.
Conclusions
In this study, a lower baseline DAS-28 and HAQ scores as
well as the absence of radiographic erosions showed a
highly significant correlation with good EULAR response,
remission and sustained responses. While a higher base-
line hemoglobin concentrations, a lower baseline HAQ
score and the absence of radiographic erosions were iden-
tified as significant predictors of sustained responses to
TNF-I in the studied patients with refractory RA. The use
of combination therapy particularly with methotrexate
favored an earlier good response and remission by 6months. Good response to TNF-I and sustained responses
showed some correlation with the decline in RF titers
during observation a finding that demands further investi-
gations in upcoming researches.
The limited sample size represents one limitation of
the study and authors recommend encouraging similar
studies in the field to provide a sufficient bank of
evidences regarding predictors of response to first and
second line biologics in refractory disease.
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